Compare abrdn Income Credit Strategies Fund (ACP) vs Ascendis Pharma A/S (ASND) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
abrdn Income Credit Strategies Fund vs Ascendis Pharma A/S — how do they compare? abrdn Income Credit Strategies Fund trades at $5.11 (market cap $641.16M), while Ascendis Pharma A/S trades at $255.5 (market cap $16.67B). The key difference: Ascendis Pharma A/S is far larger — about 26× abrdn Income Credit Strategies Fund's market cap, and abrdn Income Credit Strategies Fund pays a 18.2% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ACP | ASND | |
|---|---|---|
Market Cap | $641.16M | $16.67B |
Sector | Financials | Health |
52-Week High | $5.98 | $277.18 |
52-Week Low | $5.01 | $189.74 |
Dividend Yield | 18.2% | — |
Enterprise Value | — | $17.04B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About abrdn Income Credit Strategies Fund
abrdn Income Credit Strategies Fund is a diversified, closed-end investment management company. Its primary goal is to generate high current income, with capital appreciation as a secondary objective. The fund mainly invests in debt and loan instruments from issuers across various industries and regions.
Read more on ACP →About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →
